Clinical trials: Tardive Dystonia
Neuroleptic-Induced Tardive Dyskinesia
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00621998
- Testing
- risperidone, olanzapine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Oral Dystonia, Tardive Dystonia
Dysport for the Treatment of OMD
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
- Trial name
- NCT01921270
- Testing
- Low Dose - AbobotulinumtoxinA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Tardive Dyskinesia (TD)
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets…
- Trial name
- NCT06731868
- Testing
- LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Luye Pharma Group Ltd.
Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- AIM-TD (NCT02291861)
- Testing
- SD-809
- Where
- 106 sites in United States, Czechia and 4 more
- Volunteers
- 298 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Dyskinesia, Medication-induced
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00175955
- Testing
- Levetiracetam
- Where
- 7 sites in Belgium, Bulgaria
- Volunteers
- 70 people
- Sponsor
- UCB Pharma
Schizophrenia and Schizoaffective Disorder, Tardive Dyskinesia
D-Serine Treatment For Tardive Dyskinesia
Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the…
- Trial name
- NCT01804920
- Testing
- D-serine
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Herzog Hospital
Tardive Dyskinesia
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- KINECT 3 (NCT02274558)
- Testing
- NBI-98854
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 234 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD)…
- Trial name
- NCT01733121
- Testing
- NBI-98854
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one…
- Trial name
- RE-Kinect (NCT03062033)
- Where
- 34 sites in United States
- Volunteers
- 70 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120…
- Trial name
- NCT01391390
- Testing
- Melatonin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing HuiLongGuan Hospital
Dystonia, Movement Disorder
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.
- Trial name
- NCT00331669
- Testing
- deep brain stimulation
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Tardive Dyskinesia, Antipsychotic Agents
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist.
- Trial name
- NCT03287778
- Testing
- Pyridoxine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Tardive Dyskinesia
Piracetam for Treatment Tardive Dyskinesia
The mechanism involved in the development of tardive dyskinesia (TD) is complicated. It now seems that several neurotransmitter systems may be affected, including dopaminergic, noradrenergic, gamma-amino-butyric acid (GABA)…
- Trial name
- NCT00190008
- Testing
- piracetam
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Beersheva Mental Health Center
Tardive Dyskinesia (TD)
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
- Trial name
- NCT03698331
- Testing
- Valbenazine
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Neurocrine Biosciences
Fibromyalgia, Mitochondrial Diseases
Heart Rate Variability in Response to Metformin Challenge
Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use).
- Conditions
- Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
- Trial name
- NCT02500628
- Testing
- Metformin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Woodinville Psychiatric Associates
Huntington Disease, Tardive Dyskinesia
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164…
- Trial name
- NCT06474650
- Testing
- LPM3770164 sustained release tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Tardive Dyskinesia (TD)
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
- Trial name
- NCT03891862
- Testing
- Valbenazine
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
The Assessment of Movement Disorders Utilizing Live Two-Way Video
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
- Trial name
- NCT01467089
- Testing
- Two way video assessment
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.
- Trial name
- NCT00468533
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Yu-Li Hospital